I can not believe they used a lung cancer trial as a comparison for the CEP results. The fact that the CEP trials are now on the bottom of the presentation when they used to be the flagship just confirms my early take that the results are nothing new. If the results were fantastic the CEP study would still be the flagship.... front and center of the presentation not at the bottom.....the focus has well and truly shifted elsewhere now.
"Likely registration indication: NOX66 in combination with palliative external beam radiotherapy for the treatment of patients with metastatic cancer (prostate and others)"
http://imagesignal.commsec.com.au/d...nZXNpZ25hbC9lcnJvcnBhZ2VzL3BkZmRlbGF5ZWQuanNw
Notice what is missing in their first registration. Phase two and three trials now only include Dart and Lupin studies . Where is the phase two trial in Georgia for the CEP trials. Scratched?
Because in the clinical data release they said........."with a Phase 2 study currently being planned and due to start before the end of 2018 Our objective now is to see how long this clinical benefit will last once we continue treatment beyond 3 months”, Kelly added."
http://www.noxopharm.com/irm/PDF/1507_1/NOXReportsNOX66ClinicalData
That time has now come. But now this latest presentation has no mention of that phase two trial?
Will there be a phase II trial as planed or not for the end of 2018.?
Also note the language even in the clinical data release.
" Noxopharm has a
major focus on developing NOX66 to enhance the anti-cancer effect of radiotherapy, both external beam radiotherapy and intravenous brachytherapy. The CEP program
complements the radio-enhancement program (known as DARRT) by providing a choice of treatment as part of the move to personalise treatment according to individual cancer features and patient needs".
What was front and center now complements what is the major focus.
My point is simple the goal posts seem to be changing and the focus is to look elsewhere now.
